Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority
program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with
confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein
Thrombosis (DVT) (Einstein-PE).
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.